408 related articles for article (PubMed ID: 30069049)
1. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
Baell JB; Leaver DJ; Hermans SJ; Kelly GL; Brennan MS; Downer NL; Nguyen N; Wichmann J; McRae HM; Yang Y; Cleary B; Lagiakos HR; Mieruszynski S; Pacini G; Vanyai HK; Bergamasco MI; May RE; Davey BK; Morgan KJ; Sealey AJ; Wang B; Zamudio N; Wilcox S; Garnham AL; Sheikh BN; Aubrey BJ; Doggett K; Chung MC; de Silva M; Bentley J; Pilling P; Hattarki M; Dolezal O; Dennis ML; Falk H; Ren B; Charman SA; White KL; Rautela J; Newbold A; Hawkins ED; Johnstone RW; Huntington ND; Peat TS; Heath JK; Strasser A; Parker MW; Smyth GK; Street IP; Monahan BJ; Voss AK; Thomas T
Nature; 2018 Aug; 560(7717):253-257. PubMed ID: 30069049
[TBL] [Abstract][Full Text] [Related]
2. MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway.
Sheikh BN; Phipson B; El-Saafin F; Vanyai HK; Downer NL; Bird MJ; Kueh AJ; May RE; Smyth GK; Voss AK; Thomas T
Oncogene; 2015 Nov; 34(47):5807-20. PubMed ID: 25772242
[TBL] [Abstract][Full Text] [Related]
3. New KAT6 inhibitors induce senescence and arrest cancer growth.
Huang F
Synth Syst Biotechnol; 2018 Dec; 3(4):244-245. PubMed ID: 30417138
[TBL] [Abstract][Full Text] [Related]
4. The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology.
Wiesel-Motiuk N; Assaraf YG
Drug Resist Updat; 2020 Dec; 53():100729. PubMed ID: 33130515
[TBL] [Abstract][Full Text] [Related]
5. Histone acetylation and histone acetyltransferases show significant alterations in human abdominal aortic aneurysm.
Han Y; Tanios F; Reeps C; Zhang J; Schwamborn K; Eckstein HH; Zernecke A; Pelisek J
Clin Epigenetics; 2016; 8():3. PubMed ID: 26767057
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Benzoylsulfonohydrazides as Potent Inhibitors of the Histone Acetyltransferase KAT6A.
Leaver DJ; Cleary B; Nguyen N; Priebbenow DL; Lagiakos HR; Sanchez J; Xue L; Huang F; Sun Y; Mujumdar P; Mudududdla R; Varghese S; Teguh S; Charman SA; White KL; Katneni K; Cuellar M; Strasser JM; Dahlin JL; Walters MA; Street IP; Monahan BJ; Jarman KE; Sabroux HJ; Falk H; Chung MC; Hermans SJ; Parker MW; Thomas T; Baell JB
J Med Chem; 2019 Aug; 62(15):7146-7159. PubMed ID: 31256587
[TBL] [Abstract][Full Text] [Related]
7. MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development.
Sheikh BN; Lee SC; El-Saafin F; Vanyai HK; Hu Y; Pang SH; Grabow S; Strasser A; Nutt SL; Alexander WS; Smyth GK; Voss AK; Thomas T
Blood; 2015 Mar; 125(12):1910-21. PubMed ID: 25605372
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents.
Priebbenow DL; Leaver DJ; Nguyen N; Cleary B; Lagiakos HR; Sanchez J; Xue L; Huang F; Sun Y; Mujumdar P; Mudududdla R; Varghese S; Teguh S; Charman SA; White KL; Shackleford DM; Katneni K; Cuellar M; Strasser JM; Dahlin JL; Walters MA; Street IP; Monahan BJ; Jarman KE; Jousset Sabroux H; Falk H; Chung MC; Hermans SJ; Downer NL; Parker MW; Voss AK; Thomas T; Baell JB
J Med Chem; 2020 May; 63(9):4655-4684. PubMed ID: 32118427
[TBL] [Abstract][Full Text] [Related]
9. The role of MOZ/KAT6A in hematological malignancies and advances in MOZ/KAT6A inhibitors.
Su J; Wang X; Bai Y; Sun M; Yao Y; Duan Y
Pharmacol Res; 2021 Dec; 174():105930. PubMed ID: 34626770
[TBL] [Abstract][Full Text] [Related]
10. MOZ increases p53 acetylation and premature senescence through its complex formation with PML.
Rokudai S; Laptenko O; Arnal SM; Taya Y; Kitabayashi I; Prives C
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3895-900. PubMed ID: 23431171
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Sharma S; Chung CY; Uryu S; Petrovic J; Cao J; Rickard A; Nady N; Greasley S; Johnson E; Brodsky O; Khan S; Wang H; Wang Z; Zhang Y; Tsaparikos K; Chen L; Mazurek A; Lapek J; Kung PP; Sutton S; Richardson PF; Greenwald EC; Yamazaki S; Jones R; Maegley KA; Bingham P; Lam H; Stupple AE; Kamal A; Chueh A; Cuzzupe A; Morrow BJ; Ren B; Carrasco-Pozo C; Tan CW; Bhuva DD; Allan E; Surgenor E; Vaillant F; Pehlivanoglu H; Falk H; Whittle JR; Newman J; Cursons J; Doherty JP; White KL; MacPherson L; Devlin M; Dennis ML; Hattarki MK; De Silva M; Camerino MA; Butler MS; Dolezal O; Pilling P; Foitzik R; Stupple PA; Lagiakos HR; Walker SR; Hediyeh-Zadeh S; Nuttall S; Spall SK; Charman SA; Connor T; Peat TS; Avery VM; Bozikis YE; Yang Y; Zhang M; Monahan BJ; Voss AK; Thomas T; Street IP; Dawson SJ; Dawson MA; Lindeman GJ; Davis MJ; Visvader JE; Paul TA
Cell Chem Biol; 2023 Oct; 30(10):1191-1210.e20. PubMed ID: 37557181
[TBL] [Abstract][Full Text] [Related]
12. The Kat in the HAT: The Histone Acetyl Transferase Kat6b (MYST4) Is Downregulated in Murine Macrophages in Response to LPS.
Shukla S; Levine C; Sripathi RP; Elson G; Lutz CS; Leibovich SJ
Mediators Inflamm; 2018; 2018():7852742. PubMed ID: 29977151
[TBL] [Abstract][Full Text] [Related]
13. KAT6A, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1.
Liu W; Zhan Z; Zhang M; Sun B; Shi Q; Luo F; Zhang M; Zhang W; Hou Y; Xiao X; Li Y; Feng H
Theranostics; 2021; 11(13):6278-6292. PubMed ID: 33995658
[No Abstract] [Full Text] [Related]
14. The histone acetyltransferase KAT6A is recruited to unmethylated CpG islands via a DNA binding winged helix domain.
Weber LM; Jia Y; Stielow B; Gisselbrecht SS; Cao Y; Ren Y; Rohner I; King J; Rothman E; Fischer S; Simon C; Forné I; Nist A; Stiewe T; Bulyk ML; Wang Z; Liefke R
Nucleic Acids Res; 2023 Jan; 51(2):574-594. PubMed ID: 36537216
[TBL] [Abstract][Full Text] [Related]
15. The lysine acetyltransferase activator Brpf1 governs dentate gyrus development through neural stem cells and progenitors.
You L; Yan K; Zou J; Zhao H; Bertos NR; Park M; Wang E; Yang XJ
PLoS Genet; 2015 Mar; 11(3):e1005034. PubMed ID: 25757017
[TBL] [Abstract][Full Text] [Related]
16. KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer.
Yu B; Luo F; Sun B; Liu W; Shi Q; Cheng SY; Chen C; Chen G; Li Y; Feng H
Adv Sci (Weinh); 2021 Oct; 8(20):e2100014. PubMed ID: 34392614
[TBL] [Abstract][Full Text] [Related]
17. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.
Turner-Ivey B; Guest ST; Irish JC; Kappler CS; Garrett-Mayer E; Wilson RC; Ethier SP
Neoplasia; 2014 Aug; 16(8):644-55. PubMed ID: 25220592
[TBL] [Abstract][Full Text] [Related]
18. Expression profiles and functional prediction of histone acetyltransferases of the MYST family in kidney renal clear cell carcinoma.
Liang F; Li X; Shen X; Yang R; Chen C
BMC Cancer; 2023 Jun; 23(1):586. PubMed ID: 37365518
[TBL] [Abstract][Full Text] [Related]
19. [KAT6B promotes LPS-triggered IL-6 production via enhancing recruitment of H3K23 acetylation to IL-6 promoter region].
Sun D; Wen Q; Wang C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Nov; 33(11):1441-147. PubMed ID: 29268844
[TBL] [Abstract][Full Text] [Related]
20. MOZ and MORF acetyltransferases: Molecular interaction, animal development and human disease.
Yang XJ
Biochim Biophys Acta; 2015 Aug; 1853(8):1818-26. PubMed ID: 25920810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]